Deutsche Bank Ag\ Arcellx, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Arcellx, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 465,690 shares of ACLX stock, worth $40.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

465,690

Previous 446,530 4.29%

Holding current value

$40.9 Million

Previous $24.6 Million 57.81%

% of portfolio

0.02%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$50.91 - $86.61 $975,435 - $1.66 Million	19,160 Added 4.29%	465,690 $38.9 Million
Q2 2024 Aug 14, 2024	SELL	$49.74 - $66.98 $62,324 - $83,925	-1,253 Reduced 0.28%	446,530 $24.6 Million
Q1 2024 May 15, 2024	BUY	$51.85 - $73.49 $16 Million - $22.7 Million	308,596 Added 221.71%	447,783 $31.1 Million
Q4 2023 Feb 14, 2024	BUY	$31.75 - $57.99 $3.81 Million - $6.96 Million	120,097 Added 629.11%	139,187 $7.72 Million
Q3 2023 Nov 09, 2023	SELL	$31.51 - $37.4 $4 Million - $4.75 Million	-126,921 Reduced 86.93%	19,090 $684,000
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $3.51 Million - $5.99 Million	127,694 Added 697.13%	146,011 $4.62 Million
Q1 2023 May 15, 2023	BUY	$26.92 - $33.94 $154,305 - $194,544	5,732 Added 45.55%	18,317 $564,000
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $3,401 - $6,534	198 Added 1.6%	12,585 $389,000
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $132,343 - $174,975	7,939 Added 178.48%	12,387 $233,000
Q2 2022 Aug 11, 2022	SELL	$7.21 - $24.43 $4,542 - $15,390	-630 Reduced 12.41%	4,448 $80,000
Q1 2022 May 13, 2022	BUY	$12.97 - $19.14 $65,861 - $97,192	5,078 New	5,078 $71,000

Others Institutions Holding ACLX

# of Institutions

205

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.85B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account